National survival trends of young adults with sarcoma: lack of progress is associated with lack of clinical trial participation - PubMed (original) (raw)
Comparative Study
. 2005 May 1;103(9):1891-7.
doi: 10.1002/cncr.20995.
Affiliations
- PMID: 15795902
- DOI: 10.1002/cncr.20995
Free article
Comparative Study
National survival trends of young adults with sarcoma: lack of progress is associated with lack of clinical trial participation
Archie Bleyer et al. Cancer. 2005.
Free article
Abstract
Background: Young adults with cancer in the U.S. have had less improvement in survival than either younger patients or older patients. The authors attempted to determine whether similar deficits have occurred in young adults with sarcomas and, if so, then why.
Methods: In 38,144 young adults with sarcoma who were diagnosed during 1975-1998 and were followed by the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results Program, the average annual percent change in 5-year survival was derived as a function of patient age. National sarcoma treatment trial data were obtained on 3242 patients who were entered onto NCI-sponsored trials during 1997-2002.
Results: 1) For patients with bone and soft-tissue sarcomas, except Kaposi sarcoma (KS), the least survival improvement occurred between age 15 years and age 45 years. For patients with KS, the pattern was reversed, with the greatest survival increase occurring among patients ages 30-44 years. 2) The lowest participation rate in NCI-sponsored sarcoma treatment trials occurred in patients ages 20-44 years. For patients with KS, the highest accrual rate occurred in patients ages 35-44 years. 3) The age-dependent survival improvement and clinical-trial accrual patterns were correlated directly (soft-tissue sarcomas, P < 0.005; bone sarcomas, P < 0.05; KS, P = 0.06), regardless of whether the accrual profile demonstrated a decline or a peak (KS) during early adulthood.
Conclusions: The lack of survival prolongation in patients age 15-44 years in the U.S. with non-KS sarcomas may have been a result of their relative lack of participation in clinical trials. If this is true, then reversing the shortfall in survival among young adults with sarcomas, as was accomplished among patients with KS, should benefit from increased clinical trial availability, access, and participation.
Published 2005 by the American Cancer Society.
Similar articles
- Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials.
Bleyer A, Budd T, Montello M. Bleyer A, et al. Cancer. 2006 Oct 1;107(7 Suppl):1645-55. doi: 10.1002/cncr.22102. Cancer. 2006. PMID: 16906507 - Cutaneous soft tissue sarcoma incidence patterns in the U.S. : an analysis of 12,114 cases.
Rouhani P, Fletcher CD, Devesa SS, Toro JR. Rouhani P, et al. Cancer. 2008 Aug 1;113(3):616-27. doi: 10.1002/cncr.23571. Cancer. 2008. PMID: 18618615 - Post-radiation sarcomas. Clinical outcome of 52 Patients.
Mavrogenis AF, Pala E, Guerra G, Ruggieri P. Mavrogenis AF, et al. J Surg Oncol. 2012 May;105(6):570-6. doi: 10.1002/jso.22122. Epub 2011 Oct 19. J Surg Oncol. 2012. PMID: 22012601 - The challenges of clinical trials for adolescents and young adults with cancer.
Ferrari A, Montello M, Budd T, Bleyer A. Ferrari A, et al. Pediatr Blood Cancer. 2008 May;50(5 Suppl):1101-4. doi: 10.1002/pbc.21459. Pediatr Blood Cancer. 2008. PMID: 18360838 Review. - Primary malignant tumors of the chest wall. The Memorial Sloan-Kettering Cancer Center experience.
Burt M. Burt M. Chest Surg Clin N Am. 1994 Feb;4(1):137-54. Chest Surg Clin N Am. 1994. PMID: 8055278 Review.
Cited by
- Ewing Sarcoma in the Pediatric Population: Predictors of Survival Within the United States.
Wells ME, Eckhoff MD, Davis W, Singh V, Rajani R, Polfer EM. Wells ME, et al. J Am Acad Orthop Surg Glob Res Rev. 2024 Oct 21;8(10):e24.00281. doi: 10.5435/JAAOSGlobal-D-24-00281. eCollection 2024 Oct 1. J Am Acad Orthop Surg Glob Res Rev. 2024. PMID: 39436736 Free PMC article. - Opportunities and Challenges in Soft Tissue Sarcoma Risk Stratification in the Era of Personalised Medicine.
Chowdhury A, Thway K, Pasquali S, Callegaro D, Gronchi A, Jones RL, Huang PH. Chowdhury A, et al. Curr Treat Options Oncol. 2024 Aug;25(8):1124-1135. doi: 10.1007/s11864-024-01244-x. Epub 2024 Jul 30. Curr Treat Options Oncol. 2024. PMID: 39080193 Review. - Proteomic features of soft tissue tumours in adolescents and young adults.
Tam YB, Low K, Ps H, Chadha M, Burns J, Wilding CP, Arthur A, Chen TW, Thway K, Sadanandam A, Jones RL, Huang PH. Tam YB, et al. Commun Med (Lond). 2024 May 18;4(1):93. doi: 10.1038/s43856-024-00522-x. Commun Med (Lond). 2024. PMID: 38762630 Free PMC article. - Geographic disparity in the distribution of cancer clinical trials in the United States and the associated factors.
Gu N, Elsisi Z, Suk R, Li M. Gu N, et al. J Manag Care Spec Pharm. 2024 Apr;30(4):376-385. doi: 10.18553/jmcp.2024.30.4.376. J Manag Care Spec Pharm. 2024. PMID: 38555628 Free PMC article. - Shifting from Equality toward Equity: Addressing Disparities in Research Participation for Clinical Cancer Research.
Warner E, Marron JM, Peppercorn JM, Abel GA, Hantel A. Warner E, et al. J Clin Ethics. 2024 Spring;35(1):8-22. doi: 10.1086/728144. J Clin Ethics. 2024. PMID: 38373334
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical